Stock V3V VITA 34 AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings VITA 34 AG Berne S.E.

Equities

V3V

DE000A0BL849

Delayed Berne S.E.
Other stock markets
 		5-day change 1st Jan Change
- CHF -.--% Intraday chart for VITA 34 AG -.--% -.--%
06-01 VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

1st Jan change Capi. Investor Rating ESG Refinitiv
VITA 34 AG Stock VITA 34 AG
-.--% 84.42M -
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+18.69% 84.15B
C+
CVS HEALTH CORPORATION Stock CVS Health Corporation
-25.20% 74.14B
B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+1.62% 26.92B
C+
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-10.46% 17.15B
B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-0.68% 16.83B
A-
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-0.73% 15.21B
A-
NATERA, INC. Stock Natera, Inc.
+72.88% 13.3B
C-
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+76.04% 12.99B
C+
PURE HEALTH HOLDING Stock Pure Health Holding
-25.79% 12.79B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
  1. Stock Market
  2. Equities
  3. V3V Stock
  4. V3V Stock
  5. Ratings VITA 34 AG